Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tristar Wellness Solutions Inc. (TWSI)
Portland, OR, US
TriStar Wellness Solutions Inc. specializes in the development, commercialization, and sale of various wound care products. The company's diverse portfolio extends to include skincare and other items specifically designed for pregnant and nursing women, marketed under the Beaute de Maman brand. They also provide solutions for bleeding and wound management, catering to a wide range of clients including surgical teams, general healthcare providers, consumers, and military markets. A key innovation from TriStar is its "Delivery Device with Invertible Diaphragm," a specialized medical applicator engineered for the safe and non-damaging internal administration of medicaments and other devices within the body. Furthermore, the company develops over-the-counter products aimed at itch suppression, and it is also involved in the development, manufacturing, and marketing of additional medical devices focused on wound care and infection control. Originally incorporated as BioPack Environmental Solutions, Inc., the company officially changed its name to TriStar Wellness Solutions, Inc. in January 2013. Based in Portland, Oregon, TriStar Wellness Solutions, Inc. ultimately faced financial difficulties, leading to a voluntary petition for liquidation under Chapter 7, filed on January 15, 2016, in the U.S. Bankruptcy Court for the District of Oregon.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -97.46% | -97.83% | -99.13% | -99.13% | -98.33% | +1,400.00% | -86.96% | -82.78% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-100.0% Q4'24: +100.0% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'24: +0.1% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+100.2% Q4'24: +100.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×— Q4'24: -2,751.25× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corporation | 9.26M | 5.22% | — | — | — | — | CO | Delaware | 2005-05-24 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Ramsey | Chief Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TWSI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
